-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: Figure 3
.
Significant cohort-effect boxplots
for PC-GrimAge, Dunedin PoAm, and Dunedin PACE.
Source: Reed et al
.
"This is the first report to explore several of the latest DNA m biological aging measures over time [.
.
.
]
A new research paper published in Aging (listed as "Aging (Albany NY)" by MEDLINE/PubMed and "Aging-us" by Web of Science), Vol.
14, No.
23, titled "Measurement of 16-year biological aging and cognitive decline based on DNA methylation: preliminary longitudinal findings from midlife.
"
DNA methylation (DNAm)-based measures of biological aging are associated with increased morbidity and mortality, but their association with cognitive decline is unclear
.
In the new study, the researchers examined changes in epigenetic clocks (based on traditional and principal components [PC] Horvath, Hannum, PhenoAge, GrimAge) and aging measurement speed (Dunedine PoAm, Dunedin pace) over 16-year intervals in 48 middle-aged adults in the longitudinal group of the Adult Health and Behavior Program (56% women, baseline age = 44.
7 years), selecting different cognitive trajectories
.
"We hypothesized that, overall, people with cognitive decline were physiologically older
than those who maintained their cognitive abilities.
"
People with cognitive decline (N = 24) were selected based on a composite score decline derived from neuropsychological tests and matched
with participants who did not show any decline (N = 24).
Multilayer models of repeated DNA m measurements in humans tested the major effects
of time, population, and time-grouped interactions.
DNAm markers increase significantly over time, often coinciding
with the interval between study visits.
There were also differences between groups: overall, PC-GrimAge in people with cognitive decline were older and aged faster (Dunedin PoAm, Dunedin pace).
There is no significant time interactome, indicating that accelerated epigenetic aging remains constant during
decline.
Older PC-GrimAge and faster aging may be particularly sensitive to
cognitive decline in midlife.
"Together, these preliminary results suggest that PC-GrimAge and DNAm-based measurement of aging velocity (Dunedin PoAm and pace) are associated with
16 years of neuropsychologically validated cognitive decline in midlife.
" This result demonstrates the need for larger studies to better examine the longitudinal association
between changes in DNA m measurements and changes in multiple cognitive domains.
Ultimately, DNA m measurement as a biomarker of cognitive function in midlife may provide preclinical markers of molecular aging mechanisms that can help identify individuals
at increased risk of cognitive impairment and dementia in later life.
”
